Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F)(the “Company” or “Isodiol”) is set to debut its newest CBD raw ingredient, Heneplex p200™, at Supply Side West in Las Vegas November 8th and 9th, 2018, booth 1557, to meet the new demand and market trend in the beverage sector.

Heneplex p200™ has the advantage of being far more versatile than traditional CBD hemp extracts and oils, which can be difficult to formulate and use to manufacture consumer good products. CBD hemp extract in an oil form sticks to just about everything, tastes bad to many users, and dissolves in few substances besides alcohols and oils. In short, formulating with CBD hemp extracts is challenging. p200™ by contrast, can simply be mixed into food and beverage products, almost without exception, including protein shakes, juices, soda, coff­ee, tea, baked goods or frozen goods, or simply added to a glass of water.

Management would also like to provide an update to its shareholders around the volatility of the stock and would like to address recent investor inquiries. The Company has not deviated from its business plan announced on June 29, 2018 and believes it is executing on its business strategies in each division with new revenue opportunities being added on a consistent basis. Further, management believes some of the Company’s business strategies are in front of market trends that will soon be recognized by the market, particularly as legalization continues to trend in a favourable direction in the United States and Mexico.

Due to recent developments with the US Hemp Bill, the Company has postponed plans of its previously announced Chinese facility expansion plans and has been focusing its resources and attention to the expected upcoming opportunities in the United States and Mexico.

On December 6, 2017, the Company announced the 100% acquisition of CN Pharma, located in Abbotsford, BC, a pharmaceutical manufacturing company. The Company believed that CN Pharma was in the latter stages of obtaining its Licensed Dealer (“LD”) status under the provisions of the Canadian Controlled Drugs and Substances, however many changes to regulatory guidelines have caused a delay. CN Pharma has reapplied for their licensing under these new cannabis regulations and is ready for inspection. The Company is hoping to receive additional feedback from Health Canada after inspection and believes CN Pharma remains in a position to obtain its license. CN Pharma will only be paid the $6,000,000 CDN in stock upon successful completion of obtaining the license.

The Company is monitoring the developing regulations surrounding CBD in Canada and believes it will be in a position for the distribution of its products in this market as regulations continue to change. Currently, the Company can supply CBD as an API to an LD in Canada from its subsidiary, BSPG Laboratories, LTD. The Company strongly believes the U.S. and other foreign markets such as the U.K. and Brazil will surpass the market opportunities in Canada that are currently getting stock market attention and as a result, Isodiol will continue to put much of its focus on the U.S. and markets outside of Canada.

Finally, the Company had previously announced its intention to up list to a major US Exchange and this intention has not changed. The Company continues to explore all of its options for a potential up listing. Further updates on this matter will be provided as they are available.

Follow Our Corporate Updates On Facebook: and on Twitter: @Isodiolintlinc

Get Social with Our Brands:

Marcos Agramont, CEO & Director


Media Contact:
Christopher Hussey
Director of Communications

Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release.

Click here to connect with Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) for an Investor Presentation. 


Green Thumb Industries Inc. (Green Thumb) (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer packaged goods company and owner of Rise™ retail stores, today announced that its executive team will participate in the following conference in March 2021:

Needham 2 nd Annual Virtual Cannabis Conference, March 3, 2021: Management will participate in one-on-one meetings.

Keep reading... Show less

In the cannabis space this week, retailer Fire & Flower Holdings (TSX:FAF,OTCQX:FFLWF) told investors it will be entering the US market through a novel strategic action.

Meanwhile, two longstanding cannabis partners ended their relationship.

Keep reading... Show less

Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development

Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.

Keep reading... Show less

The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.

With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.

Keep reading... Show less